A Aralex Aachen research explorer

May 22, 2017 review Open access

Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data

DOI: 10.1634/theoncologist.2017-0015 Full text (OA) OpenAlex

Authors 0

Author list not loaded yet.

Cited by 4 stored of 175

A Prospective Multicenter Observational Study Investigating the Concordance Between Patient-Reported Hearing Loss and Commonly Used Ototoxicity Grading Systems in Patients Treated with Platinum-Based Chemotherapy
2026 Annals of Otology Rhinology & Laryngology article Neuroscience Hearing, Cochlea, Tinnitus, Genetics

0

citations
Effect of hydration schedules on dose‐limiting toxicity in patients with head and neck squamous cell carcinoma treated with cisplatin
2025 British Journal of Clinical Pharmacology article Medicine Head and Neck Cancer Studies Open access

4

citations
The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin‐based chemoradiotherapy in patients with head and neck squamous cell carcinoma
2024 Head & Neck article Medicine Head and Neck Cancer Studies Open access

1

citations
Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol
2023 PLoS ONE article Medicine Head and Neck Cancer Studies Open access

12

citations

4 results

References 0